

# Laura J. Weston

Terrebonne, Oregon

[laura@lonepinecmc.com](mailto:laura@lonepinecmc.com)  
[www.linkedin.com/in/lauraweston](http://www.linkedin.com/in/lauraweston)

858-922-7881

---

## **ADDENDUM – PATENTS, PUBLICATIONS, AND PRESENTATIONS**

### **PATENTS**

**US Patent 9,522,117** – December 20, 2016; *Bromocriptine Formulations*; Cincotta A, Bowe C, Stearns P, Weston L, inventors; VeroScience LLC, assignee.

**US Patent 9,192,576** – November 24, 2015; *Bromocriptine Formulations*; Cincotta A, Bowe C, Stearns P, Weston L, inventors; VeroScience LLC, assignee.

**US Patent 8,993,599** – March 31, 2015; *Pharmaceutical Formulations Useful for Inhibiting Acid Secretion and Methods for Making and Using Them*; Hall W, Olmstead K, Weston L, inventors; Santarus, Inc., assignee.

**US Patent 8,613,947** – December 24, 2013; *Bromocriptine Formulations*; Cincotta A, Bowe C, Stearns P, Weston L, inventors; VeroScience LLC, assignee.

**US Patent 8,431,155** – April 30, 2013; *Bromocriptine Formulations*; Cincotta A, Bowe C, Stearns P, Weston L, inventors; VeroScience LLC, assignee.

### **PATENT APPLICATIONS**

**US Patent Application 201700270871** – January 26, 2017; *Bromocriptine Formulations*; Cincotta A, Bowe C, Stearns P, Weston L, inventors; VeroScience LLC, assignee.

**US Patent Application 20150202226** – July 23, 2015; *Pharmaceutical Formulations Useful for Inhibiting Acid Secretion and Methods for Making and Using Them*; Hall W, Olmstead K, Weston L, inventors; Santarus, Inc., assignee.

**US Patent Application 20140370104** – December 18, 2014; *Pharmaceutical Formulation And Method For Treating Acid-Caused Gastrointestinal Disorders*; Hall W, Olmstead K, Weston L, inventors; Santarus, Inc., assignee.

**US Patent Application 20140271853** – September 18, 2014; *Novel Formulations of Proton Pump Inhibitors and Methods of Using These Formulations*; Hall W, Weston L, Olmstead K, Gallo L, Bowe C, inventors; Santarus, Inc, assignee.

**US Patent Application 20100297220** – November 25, 2010; *Pharmaceutical Formulation And Method For Treating Acid-Caused Gastrointestinal Disorders*; Hall W, Olmstead K, Weston L, inventors; Santarus, Inc., assignee.

**US Patent Application 20090092658** – April 09, 2009; *Novel Formulations of Proton Pump Inhibitors and Methods of Using These Formulations*; Hall W, Weston L, Olmstead K, Gallo L, Bowe C, inventors; Santarus, Inc, assignee.

**US Patent Application 20050031700** – February 10, 2005; *Pharmaceutical Formulations and Method for Treating Acid-Caused Gastrointestinal Disorders*; Hall W, Olmstead K, Weston L, inventors; Santarus, Inc., assignee.

## **PUBLICATIONS AND PRESENTATIONS**

### **Synthesis, Structure, and Properties of $A_{14}AlSb_{11}$ (A = Ca, Sr, Ba)**

Authors: Brock, S.L.; Weston, L.J.; Olmstead, M.M.; Kauzlarich, S.M.

Published: Journal of Solid State Chemistry, 107, 513-523 (1993).

Presented: National Meeting of the American Chemical Society, 1992, by L.J. Weston.  
National Conference for Undergraduate Research, 1992, by L.J. Weston.

*Abstract -  $A_{14}AlSb_{11}$  (A = Ca, Sr, Ba) is synthesized by reacting the elements in stoichiometric amounts at high temperature (1250°C). Single-crystal X-ray diffraction data (130 K:  $a = 17.493(4) \text{ \AA}$ ,  $c = 23.480(8) \text{ \AA}$  (Sr);  $a = 18.293(2) \text{ \AA}$ ,  $c = 24.222(9) \text{ \AA}$  (Ba)) were refined (tetragonal,  $I4_1/acd$  (142),  $Z = 8$ ;  $R = 4.02\%$ ,  $R_w = 4.26\%$  (Sr);  $R = 3.71\%$ ,  $R_w = 4.34\%$  (Ba)) and showed these compounds to be isostructural to  $Ca_{14}AlSb_{11}$ . Single-crystal X-ray and microprobe data indicate that these compounds are slightly deficient in Al. Temperature-dependent resistivity measurements show that these materials are intrinsic semiconductors with activation energies of 0.0143, 0.0667, and 0.4814 eV for the Ca, Sr, and Ba analogs, respectively.*